Caplin Point Q3 FY26 profit up 18%: valuation metrics

Why Caplin Point is in focus

Caplin Point Laboratories Limited (NSE: CAPLIPOINT) stayed on investor watchlists after a set of earnings updates, regulatory developments, and fresh market metrics around the stock’s trading levels and valuation. The company operates a pharmaceutical business model focused predominantly on emerging markets in Latin America and Africa, and it also has a growing presence in regulated markets such as the US through subsidiaries Caplin Steriles and Caplin Steriles USA Inc.

The December 2025 quarter (Q3 FY26) numbers showed year-on-year growth in both revenue and profit on a consolidated basis. At the same time, the stock saw mixed near-term moves across different sessions, including a reported decline on the day the Q3 earnings update was cited.

Q3 FY26 earnings: higher sales and profit

For the quarter ended December 2025, Caplin Point reported consolidated net profit of ₹163.88 crore, up 17.93% from ₹138.96 crore in the corresponding quarter of the previous year. Sales rose 10.10% to ₹542.77 crore from ₹492.96 crore.

Operating metrics also improved alongside topline growth. The operating profit margin (OPM) was reported at 34.94% for the December 2025 quarter versus 32.92% in the December 2024 quarter. Profit before tax (PBT) increased to ₹203.89 crore from ₹177.26 crore, while profit before depreciation and tax (PBDT) rose to ₹223.17 crore from ₹193.46 crore.

In the market update cited alongside these results, the stock was reported down 1.49% at ₹1,706.90 on the BSE.

September 2025 quarter: another quarter of growth

For the quarter ended September 2025, Caplin Point’s consolidated net profit was reported at ₹154.45 crore, up 18.08% from ₹130.80 crore in the September 2024 quarter. Sales increased 10.54% to ₹534.04 crore from ₹483.10 crore.

The September quarter update also listed OPM at 35.42% compared with 34.08% a year earlier. PBDT rose to ₹219.40 crore from ₹185.22 crore, and PBT increased to ₹201.00 crore from ₹168.46 crore.

Separately, a standalone update for the September 2025 period reported net sales of ₹175.18 crore, down 15.75% year-on-year.

Regulatory update: USFDA approval and the stock reaction

A key development referenced was a USFDA approval for Methylprednisolone Acetate injection. The stock reaction was noted as shares up 2% on this update, timestamped Jan 28, 2026 (09:21 AM).

While the dataset does not provide additional details on volumes or product launch timelines, the mention signals that investors were tracking progress in the regulated markets segment, where Caplin Steriles and Caplin Steriles USA Inc. operate.

Trading levels and liquidity snapshot

Several market statistics were listed for the stock’s price history and recent trading behaviour. The all-time high was given as ₹2,641.00 and the all-time low as ₹34.80. The 52-week high and low were listed at ₹2,395.00 and ₹1,500.30, respectively.

Liquidity indicators included a 20-day average volume of 92,914 shares and a 20-day average delivery percentage of 52.13%. Beta was listed at 0.90 in one metrics table, while another snapshot showed beta (1Y) at 1.76.

Valuation and balance sheet indicators

The dataset provided multiple valuation snapshots. TTM EPS was listed as ₹80.74 with +19.08% YoY growth. One section showed TTM PE at 22.89 (marked as average PE), while another showed PE ratio at 22.76. Separately, a “Key stats” block listed price-to-earnings (TTM) at 27.25, and another line listed 31.35.

Price-to-book (P/B) was shown at 4.23 (average P/B) and also at 4.88 in the key metrics table. Book value per share appeared as ₹437.46 in one place and ₹379.73 in another. Dividend yield was shown around 0.32% to 0.33% across sections.

Sector comparisons were also included. Sector PE was listed at 41.89 (and 41.67 in another section), while a sector PB of 6.14 and sector dividend yield of 0.52% were also provided.

Growth, margins, and scale: longer-term indicators

Caplin Point’s multi-year trend statements in the dataset pointed to growth above industry averages on some measures. Over the last 5 years, revenue was stated to have grown at a yearly rate of 17.59% versus an industry average of 9.86%. Net income growth over the same period was listed at 20.06% versus an industry average of 19.71%.

The dataset also noted an “increasing market share” shift from 0.36% to 0.48% over 5 years. Dividend commentary stated the company has increased dividends consistently over the last 5 years.

Dividend: yield, declared payout, and trend

The current dividend yield was stated as 0.33% in multiple places. A dividend declaration was listed as ₹3.00 on 12 Sep, 2025. Another dividend series showed DPS values rising over time and the latest DPS in that table was ₹6.00, alongside a declining payout ratio that reached 0.07 in the last period shown.

One note also explained the yield math: an investment of ₹1,000 in the stock was expected to generate an annual dividend of ₹3.26, consistent with a 0.33% yield.

Key numbers at a glance

Quarterly performance summary (consolidated)

What investors typically watch next

The dataset ties Caplin Point’s near-term attention to two tracks: quarterly execution and progress in regulated markets. Q3 FY26 showed a faster pace of profit growth than revenue growth, alongside improved OPM compared with the year-ago quarter.

On the regulatory side, the USFDA approval update and the stock’s immediate move indicated that approvals related to Caplin Steriles’ portfolio are closely tracked. Alongside this, the company’s dividend pattern and payout ratios offer another layer of monitoring for investors who follow cash returns.

Conclusion

Caplin Point’s December 2025 quarter delivered consolidated sales of ₹542.77 crore and net profit of ₹163.88 crore, with year-on-year growth of 10.10% and 17.93%, respectively. The broader snapshot also highlighted key market levels, mixed valuation readings across sources, and a dividend trend described as consistently increasing over five years. Future attention is likely to remain on subsequent quarterly updates and further regulated-market milestones following the USFDA approval mentioned for Methylprednisolone Acetate injection.